Form 4: Cardlytics CFO Sells Shares for Tax Obligations

Cardlytics CFO Alexis DeSieno sold 8,493 shares of common stock to cover tax withholdings following the vesting of 14,350 restricted stock units.

Summary

• Alexis DeSieno, Chief Financial Officer of Cardlytics, Inc. (CDLX), reported transactions involving the company's common stock.
• On October 1, 2025, 14,350 restricted stock units (RSUs) vested, leading to the acquisition of 14,350 shares of common stock.
• Following the vesting, on October 2, 2025, DeSieno sold 8,493 shares of common stock at a weighted average price of $2.271 per share.
• The sale was solely to satisfy tax withholding obligations that resulted from the RSU vesting.
• After these transactions, DeSieno beneficially owns 195,417 shares of common stock directly and 28,699 derivative securities (RSUs).
• The original RSU award was for 114,796 shares, vesting in eight equal installments, with the October 1, 2025 vesting being one such installment.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to executive compensation (RSU vesting and tax-related sale), which is generally neutral in sentiment as it does not reflect a discretionary sale or new fundamental information about the company's performance.

Positives

• Vesting of 14,350 restricted stock units (RSUs) on October 1, 2025, represents a scheduled compensation event for the Chief Financial Officer.
• The sale of shares was explicitly stated to be solely for satisfying tax withholding obligations, indicating it was not a discretionary sale based on market outlook.

Negatives

• A reduction of 8,493 shares in direct beneficial ownership by a key executive, even if for tax purposes, slightly decreases insider alignment with shareholders.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "The Reporting Person did not sell shares for any other purpose [than to satisfy tax withholding obligations]."

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of restricted stock units and the subsequent sale of shares to cover tax liabilities. Such transactions are common across industries as part of executive compensation packages and typically do not reflect a change in the company's operational performance or strategic direction.

Stakeholder Impact

• Shareholders: Minor impact due to a slight increase in shares available in the market from the sale, but the transaction is routine and tax-driven, not indicative of a change in executive confidence.
• Employees: The vesting of RSUs demonstrates the company's ongoing executive compensation structure, which can be a positive for employee retention and motivation.

Next Steps

• Future RSU award installments are scheduled to vest on January 1, 2026, and April 1, 2026, provided the Reporting Person remains employed by the Issuer.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares solely to cover tax obligations. Such an event is a standard part of executive compensation and does not provide new fundamental information about Cardlytics' operational performance, strategic outlook, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not alter the existing investment thesis.

Keywords

Cardlytics, CDLX, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Executive Compensation, Alexis DeSieno, Chief Financial Officer